Investigational Blisibimod Improved Severe Lupus Disease in New Study

New results of a Phase 2 study showed beneficial effects of the investigational B-cell inhibitor blisibimod among patients with severe lupus disease. Pre-defined response rates were 41.7% for those receiving blisibimod at the highest dose of 200 mg weekly compared with 10.6% of patients given placebo. Results were published in Annals of the Rheumatic Diseases.